Becton, Dickinson and Company
BDXB
New York Stock Exchange48.16
USD
+0.66
- -
CIK
0000010795
ISIN
US0758874061
CUSIP
075887406
Return %
Stock
S&P500
1Y
-2.63
18.21
3Y
-9.47
64.38
5Y
11.69
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Thomas E. Polen Jr.
- Full Time Employees
- 77,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1 Becton Drive Franklin Lakes NJ United States of America 07417-1880
- IPO Date
- May 21, 2020
- CIK
- 0000010795
- Website
- bd.com
- Similar Companies
- Business
- Becton, Dickinson and Company (BD) manufactures and sells a broad range of medical devices, instrument systems, reagents, and diagnostics solutions worldwide. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company operates through three primary segments: BD Medical, which provides medication delivery systems including syringes, IV catheters, and Pyxis automated dispensing cabinets; BD Life Sciences, offering preanalytical sample management, flow cytometry instruments such as FACSDiscover A8 cell analyzers, microbiology diagnostics, and molecular assays; and BD Interventional, delivering surgical products, vascular access devices, venous stents, urology solutions, and critical care monitoring like the HemoSphere Alta monitor. BD serves hospitals, clinics, physicians, pharmaceutical companies, research labs, and public health agencies across virtually every country, with over 70,000 employees supporting infection prevention, drug delivery, surgical procedures, and advanced diagnostics. Recent developments include the September 2024 commercial release and capacity expansion of BD Neopak XtraFlow glass prefillable syringes for biologic therapies; the October 2025 launch of the AI-enabled BD Incada Connected Care Platform integrated with the next-generation BD Pyxis Pro automated medication dispensing solution; the December 2025 global release of three- and four-laser configurations for FACSDiscover A8 cell analyzers combining spectral analysis with real-time imaging; the September 2024 acquisition of Edwards Lifesciences' Critical Care unit; and ongoing exploration of strategic options for its Life Sciences division announced in early 2025, potentially including a sale or spin-off to refocus as a pure medtech firm.